Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy by Olivotto, I. et al.
20 December 2021
Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy / Olivotto I.; Maron B.J.;
Tomberli B.; Appelbaum E.; Salton C.; Haas T.S.; Gibson C.M.; Nistri S.; Servettini E.; Chan R.H.; Udelson J.E.; Lesser
J.R.; Cecchi F.; Manning W.J.; Maron M.S.. - In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. - ISSN
0735-1097. - STAMPA. - 62(2013), pp. 449-457. [10.1016/j.jacc.2013.03.062]
Original Citation:






(Article begins on next page)
La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla
Policy per l'accesso aperto dell'Università degli Studi di Firenze (https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf)
Availability:
This version is available at: 2158/1176059 since: 2019-11-03T11:50:45Z
Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:
FLORE






IMPACT OF OBESITY  
ON THE PHENOTYPE AND CLINICAL COURSE  
OF HYPERTROPHIC CARDIOMYOPATHY  
______________________________ 
  
Iacopo Olivotto MD1, Barry J. Maron MD2, Benedetta Tomberli MD1, Evan Appelbaum MD3,4,  
Carol Salton3,4, Tammy S. Haas RN2, C Michael Gibson MD3,4, Stefano Nistri MD1,  
Eleonora Servettini MD 1, Raymond H. Chan4, MD James E. Udelson MD5, John R. Lesser MD2,  
Franco Cecchi1, Warren J. Manning MD3,4 and Martin S. Maron MD5 
 
Referral Center for Myocardial Diseases, Azienda Ospedaliera Universitaria Careggi, Florence Italy; 
2Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota; 
3Department of Medicine, Cardiovascular Division, Beth Israel Deaconess Hospital and Harvard Medical 
School, Boston, Massachusetts; 4PERFUSE Core Laboratory and Data Coordinating Center, Harvard Medical 
School, Boston, Massachusetts; 5Division of Cardiology, Tufts Medical Center, Boston, Massachusetts. 
 
Running Head:  Obesity and LV mass in HCM 
Total word count: 5,461 
 
Address for correspondence: Dr. Iacopo Olivotto, MD 
    Dipartimento Cuore e Vasi 
    Azienda Ospedaliera Universitaria Careggi 
    Viale Pieraccini 19, 50134 Firenze, Italy 
    Tel/Fax: 39 055 7949335 
    Email: olivottoi@aou-careggi.toscana.it 
 
Conflict of Interest Disclosures: None. 
Acknowledgments: This work was supported by the Italian Ministry for University and Research (PRIN), 





Background. It is unresolved whether clinical variables promoting left ventricular (LV) hypertrophy 
in the general population, such as obesity, may influence cardiac phenotypic and clinical course in patients 
with hypertrophic cardiomyopathy (HCM). Therefore, we assessed the impact of body mass index (BMI) on 
disease expression in a large HCM cohort. Methods. In 275 adult HCM patients (age 48±14 years; 70% 
male), we assessed the relation of BMI to LV mass (determined by cardiovascular magnetic resonance 
[CMR] and heart failure progression. Results. At multivariate analysis, BMI proved an independent predictor 
of the magnitude of hypertrophy: pre-obese and obese HCM patients (BMI 25-30 and >30 kg/m2, 
respectively) showed a 65% and 310% increased likelihood of an LV mass in the highest quartile (>120 
g/m2), compared to normal weight patients (BMI <25; hazard ratio [HR] 1.65, 95%CI 0.73-3.74; p=0.22 and 
3.1, 95%CI 1.42-6.86;p=0.004, respectively). Other predictors of LV mass >120 g/m2 were LV outflow 
obstruction (HR 4.9; 95%CI 2.4-9.8; p<0.001), systemic hypertension (HR 2.2; 95%CI 1.1-4.5; p=0.026) and 
male gender (HR 2.1; 95%CI 0.9-4.7; p=0.083). Over a 4.7±2.3 year follow-up, obese patients showed a 3.6 
HR (95%CI 1.2-10.7; p=0.02) for developing NYHA class III symptoms compared to non-obese patients, 
independent of outflow obstruction. Of 31 patients in NYHA class III at final evaluation, 4 (13%) were 
normal weight, 7 (23%) were pre-obese and 20 (65%) were obese (p=0.037). Conclusions. In HCM patients, 
extrinsic factors such as obesity can independently impact phenotypic expression and LV mass, as well as 
dictate the progression of heart failure symptoms. 








Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease, characterized by 
heterogeneous phenotypic expression with extreme diversity in the pattern and extent of left ventricular 
hypertrophy (LVH), due to molecular pathways and triggers that remain largely unexplained (1-5). In the 
majority of HCM patients, the disease is associated with mutations in genes encoding proteins of the 
cardiac sarcomere, most commonly beta-myosin heavy chain and myosin-binding protein C (1-3). While 
these molecular defects are considered responsible for the development of LVH, there is currently no 
conclusive evidence to explain the variability in phenotypic expression of HCM, ranging from massive 
degrees to absence of LVH even within the same family (1,4-6).  
Among several hypotheses, the interplay of modifier genes and environmental factors has been 
commonly offered as a potential explanation for phenotypic diversity (7,8). To date however, the possibility 
of an environmental modulation of the HCM phenotype remains speculative, and even the impact of an 
obvious candidate variable, such as obesity, known to promote LVH in the general population, is unresolved 
(9-13).  
In addition, it is unknown whether the adverse metabolic and hemodynamic effects of obesity, to 
which HCM patients may be exposed during the long-term course of their disease, ultimately affect 
symptomatic status and prognosis (14,15). Therefore, the present study was designed, in a large cohort 
studied with cardiac magnetic resonance (CMR), to assess the impact of body mass index (BMI) on the 






 The study cohort comprised 275 adult patients with HCM (age >18 years, mean 48±14 years, 70% 
male, maximum LV wall thickness 21±5 mm) consecutively referred for CMR at 3 participating referral 
centers in the U.S. and Italy: Minneapolis Heart Institute Foundation, Minneapolis, MN. (n=168); Tufts 
Medical Center, Boston, MA. (n=45), and Careggi University Hospital, Florence, Italy (n=62). Diagnosis of 
HCM was based on two-dimensional echocardiographic evidence of a hypertrophied, nondilated LV 
(maximal wall thickness ≥15 mm), in the absence of another cardiac or systemic disease that could produce 
the magnitude of hypertrophy evident (1,3). We excluded significant atherosclerotic coronary artery 
disease (>50% stenosis in 1 major artery) by virtue of 2 specific clinical or CMR criteria: 1- no study patient 
experienced an acute coronary event associated with increased cardiac enzymes or Q waves on ECG and 2- 
in all patients with LGE distributed in a single coronary vascular territory, hemodynamically significant 
coronary artery disease was excluded by arteriography or computed tomography angiogram. Furthermore, 
patients with prior cardiac surgery (including septal myectomy), alcohol septal ablation, chronic renal 
failure and type I diabetes mellitus were excluded. The study protocol was approved by the respective 
Internal Review Boards or research ethics committees of each institution, and written inform consent was 
obtained from each subject.  
Definitions 
Body mass index (BMI) was calculated as weight/(height x height) and expressed in kg/m2. Patients 
were classified as Normal Weight (BMI range <25 kg/m2), Pre-Obese (25-30 kg/m2) and Obese (>30 kg/m2), 
according to existing guidelines (14). Type 2 diabetes was defined (and treated) according to standard 
guidelines (16).  
Systemic hypertension, was diagnosed based on resting blood  pressure values >140/90 mmHg on 
≥3 different examinations and treated medically to optimize blood pressure control, as per standard 
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international guidelines (16). All patients with hypertension had a diagnosis of HCM based on 1 or more of 
the following criteria: 1) HCM-causing sarcomere gene mutation or family history of HCM; 2) onset of 
hypertension occurring years after the diagnosis of HCM; 3)  maximum LV wall thickness exceeding that 
expected by hypertension alone (i.e. >20 mm); 4) presence of marked mitral leaflet elongation (17), 5) 
dynamic LV outflow obstruction (≥30 mmHg) under resting conditions (18); 6) distribution of late 
gadolinium enhancement (LGE) by contrast CMR consistent with HCM (i.e. preferentially mid-wall or 
transmural, and not confined to a single coronary vascular territory) (3,5,19).  
Echocardiography 
Echocardiographic studies were performed with commercially available instruments. LV 
hypertrophy was assessed with two-dimensional echocardiography, and the site and extent of maximal wall 
thickness were identified. Maximal end-diastolic LV wall thickness was taken as the dimension of greatest 
magnitude at any site within the chamber. LV outflow obstruction, due to mitral valve systolic anterior 
motion and mitral-septal contact, was identified by a peak instantaneous outflow gradient ≥30 mm Hg 
occurring under basal conditions (n=57) (18). Two-hundred and eighteen patients were nonobstructive at 
rest, (basal gradient <30 mmHg), of whom 105 (age 43±13 years, 72% males) and underwent maximal 
symptom-limited exercise echocardiography, as previously described (18); 50 developed dynamic gradients 
≥30 mmHg during effort or recovery (range 48-155 mmHg), and were considered to have provokable 
outflow obstruction.  
Cardiovascular Magnetic Resonance (CMR)  
All CMR examinations were performed using commercially available scanners (Philips ACS-NT 1.5T 
Gyroscan-Intera, Best, Netherlands) and a commercial cardiac coil. Electrocardiographic gated, steady-
state, free precession breath- hold cines in sequential 10 mm short-axis slices (no gap) were acquired 
starting parallel to the atrioventricular ring and covering the entire ventricle. LV end-diastolic and end-
systolic volumes, LV mass and wall thickness were calculated with commercially available work-stations 
(View Forum, Philips Medical System, Netherlands) (17,19).  
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For calculation of LV mass, the endocardial and epicardial borders of the LV were manually 
planimetered on successive short-axis cine images at end-diastole. The most basal slice at end-diastole was 
visually inspected and, if ventricular myocardium was present, it was planimetered and included in the 
mass calculation. If myocardium but no intracavitary blood pool was present on the most apical slice, it was 
included in the mass calculation by planimetering only the epicardial border. Particular care was taken to 
avoid including papillary muscles in the LV mass calculation. LV mass was derived by the summation of discs 
method and multiplying myocardial muscle volume by 1.05 g/cm3 (19). LV mass was indexed to body 
surface area (BSA). Maximum end-diastolic LV wall thickness was taken as the dimension of greatest 
magnitude at any site within the LV wall. CMR measurements were performed by an experienced 
investigator at each center, blinded to the results of echocardiography. The presence of LGE was assessed 
by visual inspection 15 minutes after intravenous administration of 0.2 mmol/kg gadolinium-DTPA 
(Magnevist, Schering; Berlin, Germany) with breath-held segmented inversion-recovery sequence 
(inversion time 240 to 300 ms) which was acquired in the same views as the cine images (19).  
Statistical Methods 
 Data were expressed as mean±SD. For the comparison of two and more than two normally 
distributed variables, we employed Student's t-test and one-way ANOVA followed by Bonferroni's post-hoc 
test, respectively. Chi-square test was utilized to compare non-continuous variables expressed as 
proportions; however, Fisher's exact test was employed when one or more cells in the comparison table 
had an expected frequency of less than 5. Independent predictors of increased LV mass index were 
assessed by stepwise (forward conditional) multivariate logistic regression analysis. Survival was assessed 
by Cox proportional hazard regression. The survival curve was constructed according to the Kaplan-Meier 
method, and comparisons were performed using the log-rank test. P-values are two-sided and considered 






Prevalence of obesity  
 The 275 HCM patients had an average BMI of 29.1±6.1 kg/m2, ranging from 16.2 to 49.3 kg/m2. 
Sixty-nine patients (25%) were in the normal weight range (BMI<25; average 22.3±2.1), 105 (38%) were 
pre-obese (BMI 25-30; average 27.4±1.4), and 101 (37%) were obese (BMI>30; average 35.4±4.8) (Table 1). 
Overall, 107 patients (39%) were found to have LV outflow obstruction (i.e. a peak instantaneous outflow 
gradient ≥30 mmHg) occurring either under basal conditions (n=57) or during physiologic exercise (n=50). 
Seventy-five patients (27%) had a history of controlled systemic hypertension and 14 (5%) had adult-onset, 
type II diabetes. LV outflow obstruction, both under resting conditions and elicited by exercise, was 
disproportionally prevalent in pre-obese and obese patients (Figure 1, Table 1). Likewise, systemic 
hypertension and diabetes were more prevalent in pre-obese and obese compared to normal weight 
patients (Table 1); 38 of the 101 obese HCM patients (38%) were also hypertensive. 
Relation of BMI to LV mass, volume and function  
Average LV mass index in the HCM patient cohort was 104±40 g/m2, ranging from 41 to 329 g/m2 
(highest quartile cut-off 120 g/m2), greater in males (109±41 g/m2 vs. 91±36 in females, p<0.001), (Table 2). 
Compared to normal weight patients, LV mass index progressively increased in pre-obese and obese 
patients: 95±46, 100±31 and 114±43 g/m2, respectively (overall p=0.005; obese patients p<0.05 vs. each 
other group)(Figure 2), reflecting a direct relationship between LV mass and BMI (correlation 
coefficient=0.23; p<0.001). Conversely, maximum LV wall thickness was virtually identical in normal weight, 
pre-obese and obese patients (22±6 mm, 21±5 mm and 21±5 mm,  respectively; p=0.27).  
Increased LV mass with respect to body weight was associated with higher LV end-diastolic volume 
index: 66±14 ml/m2 in normal weight, 77±18 ml/m2 in pre-obese and 83±20 ml/m2 in obese patients (overall 
p<0.001) (Figures 3 and 4). Nevertheless, average LV end-diastolic dimension remained within the normal 
range for each group (i.e., nondilated LV cavity) (Table 2). Notably, when the subset of 168 nonobstructive 
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HCM patients was analyzed separately, the direct correlation of BMI and LV mass index persisted 
(correlation coefficient 0.22,p=0.004).  
Conversely, LV systolic function, as expressed by ejection fraction (EF), did not differ among the 3 
BMI classes (p=0.86); by virtue of greater end-diastolic volumes, stroke volume index increased from 
normal weight to pre-obese to obese HCM patients, whereas mass/volume ratio was unchanged (Table 2). 
Prevalence of LGE was increased in pre-obese and obese HCM patients (48% and 55%, respectively) 
compared to the normal weight patients (28%, overall p=0.001). However, average %LV mass occupied by 
LGE in individual patients did not differ between the subgroups (overall p=0.43) (Table 2).   
Systemic hypertension was associated with increased LV mass index in our HCM cohort (118±44 
g/m2 vs. 98±36 in normotensive; p<0.001), although type 2 diabetes was not (LV mass index 104±41 g/m2  
vs. 104±21 in non-diabetic patients; p=0.98).  Patients who were both obese and hypertensive had LV mass 
index values of 126±44 g/m2, compared to 93±42 g/m2 in those patients who were neither obese nor 
hypertensive (p<0.001). 
Predictors of LV mass  
A multivariate regression model was constructed to identify variables independently associated 
with greater magnitude of LV hypertrophy, defined by a LV mass in the highest quartile for the overall 
cohort, or >120 g/m2. The model included BMI, age, gender, resting or provokable LV outflow obstruction, 
systemic hypertension and type 2 diabetes. BMI proved an independent predictor of LV mass >120 g/m2, 
with an hazard ratio (HR) per unit increase of 1.07 (95%CI 1.01-1.13; p=0.019).  
Pre-obese HCM patients showed 65% increased likelihood of assignment to the highest LV mass 
index quartile, compared to normal weight patients (HR: 1.65; 95%CI: 0.73-3.74; p=0.22), while in obese 
patients this likelihood increased >300% (HR: 3.1; 95%CI: 1.42-6.86; p=0.004). Other variables associated 
with LV mass >120 g/m2 were:  resting or provokable outflow obstruction (HR: 4.9; 95%CI: 2.4-9.8; 




Symptomatic status and outcome 
Over a 4.7±2.3 year follow-up after CMR, there were 25 deaths (or equivalents), of which 6 were 
non-cardiac and 19 were HCM-related. Of the latter 19 death events, 12 were sudden (including 7 deaths, 2 
patients resuscitated from cardiac arrest and 3 appropriate ICD discharges for ventricular 
tachycardia/fibrillation). In addition, there were 6 heart failure-related events (3 deaths and 3 heart 
transplants), and 1 postoperative death (surgical septal myectomy). There was no difference in all-cause 
mortality among the 3 BMI classes (Figure 5).  
In the 256 patients who were alive at the end of follow-up, those with obesity were however 
almost 3-fold more likely to have developed progressive NYHA class III-IV symptoms at most recent 
evaluation, compared to normal weight patients (overall p=0.027) (Figure 5). Noticeably, of those 31 
survivors in NYHA class III at the end of follow-up, 4 (13%) were normal weight, 7 (23%) were pre-obese and 
20 (65%) were obese (p=0.037). Independent predictors of NYHA class III symptoms at end of follow-up 
were obesity (HR 3.6; 95%CI 1.2-10.7; p=0.02), female gender (HR 4.3; 95%CI 1.5-12.4; p=0.007) and LV 
outflow obstruction (HR 2.7; 95%CI 0.9-7.8; p=0.07); whereas age, history of atrial fibrillation and 
hypertension were not.   
 
DISCUSSION 
Obesity and the HCM phenotype  
In HCM, the primary morphologic expression of LV hypertrophy has historically been considered 
solely a consequence of the gene mutation, with no evidence to date that environmental variables can 
influence phenotypic expression. (2,5,7,8). However, the extreme heterogeneity of phenotypic expression 
among HCM patients, even in family members sharing the same mutation (6), implies that other 
determinants of cardiac morphology must be operative (2,3-5). For example, greater LV mass has been 
observed in male patients and those with dynamic LV outflow obstruction (18), suggesting the disease 
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phenotype may be sensitive to environmental modulation (20). In order to address this issue, we have 
considered whether obesity, an established cardiovascular risk factor known to promote LVH in the general 
population, may influence the magnitude of LV mass and prognosis in a large HCM cohort.  
Our data demonstrate that obesity is independently associated with increased LV mass, 
establishing a novel principle that environmental variables can influence disease expression in a primary 
genetic cardiomyopathy such as HCM (19), a concept also relevant to other cardiomyopathies (20). Indeed, 
BMI was a powerful predictor of severe LV mass increase in our HCM patients, independent of other 
important determinants such as gender and dynamic LV outflow obstruction (19), as well as systemic 
hypertension. Furthermore, obesity appeared to have an important role in determining the progression and 
severity of heart failure symptoms (5).  
In our HCM patients, the relationship between BMI and LV mass became particularly evident for 
BMI values >30. Obese patients were >3 times as likely to have a marked increase in LV mass exceeding 120 
g/m2, compared to those of normal weight.  This increase in LV mass was driven primarily by greater end-
diastolic volume (which nevertheless remained within normal limits when indexed to body size). In the 
general population, LV remodeling associated with chamber enlargement is an established consequence of 
obesity, which normalizes stroke volume index in the presence of increased oxygen requirement, thereby 
reflecting a physiologic adaptation to body weight (12,13,15,21,22). This principle was also supported by 
our observation that greater LV cavity volume in obese HCM patients was accompanied by preserved 
systolic function, resulting in an increased stroke volume index (12,13,21,22). 
Notably, absolute LV wall thickness was unaffected by body weight, with obese patients showing 
maximum thickness values virtually identical to those in patients of normal weight. This finding suggests 
that the 2 features which most differentiate HCM from secondary forms of LVH, i.e. the asymmetric 
distribution of LV thickening and the often marked degree of regional hypertrophy, are largely unaffected 
by environmental modulation (4,7). Therefore, neither the current clinical diagnostic criteria for HCM nor 
11 
 
decision-making for primary prevention of sudden death with ICDs (both based on maximum absolute LV 
wall thickness) (1,3,23-25), require adjustment with respect to BMI in adult patients.  
Obesity and symptomatic status/outcome 
During an average follow-up of almost 5 years, obese HCM patients had a 3.6-fold increased risk of 
developing severe functional limitation (NYHA functional class III) compared to non-obese patients, 
independent of other known determinants of heart failure symptoms such as outflow obstruction and atrial 
fibrillation (26). It was, however, difficult to ascertain precisely what proportion of functional limitation was 
due directly to obesity, as opposed to the consequences of HCM disease state (1,3). Nevertheless, 
symptomatic obese patients showed no impairment in LV ejection fraction, indicating that their severe 
disease profile was not due to progressive systolic dysfunction (or “end-stage” HCM) (5). In the general 
population, obesity is an important predictor of heart failure (14,15,27), associated with multiple and often 
profound changes in the cardiovascular system, including increased cardiac oxygen requirement, 
neurohormonal activation, increased oxidative stress, increased cardiac output and expanded central blood 
volume causing hemodynamic overload in the face of reduced cardiac efficiency (15,27). Likewise, our data 
suggest that excessive body weight in HCM patients may impact importantly on symptom progression, 
potentially triggering a cycle of event in which obesity leads to an obligatory sedentary lifestyle, further 
increases in BMI and, ultimately, worsening of heart failure symptoms (14). Whether significant weight loss 
will lead to reduction of symptoms and LV mass in obese HCM patients remains unresolved, although these 
data support future longitudinal studies aimed at clarifying this issue (30). 
 On the other hand, obesity itself did not confer an independent survival disadvantage during 
follow-up in our HCM cohort. This finding suggests that other variables are more relevant than body weight 
in determining the prognosis of this complex disease (3,5,26), and is consistent with the elusive relationship 
of body weight to outcome in cardiovascular disease at large (27,28). Indeed, while obesity is associated 
with increased morbidity and mortality in the general population (9,14,27), a high BMI represents a strong 
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independent predictor of favorable outcome in patients with chronic heart failure, a phenomenon  known 
as the “obesity paradox” (28).  
Significance of LV outflow obstruction and hypertension 
LV outflow obstruction was >2-fold more prevalent in obese HCM patients compared to those of 
normal weight, and associated with further increase in LV mass (17-19). Although the mechanisms 
accounting for this relationship are uncertain, the abnormally increased adrenergic drive associated with 
obesity may predispose to development of intraventricular gradients (29). Such observation may suggest 
that excess LV hypertrophy in obese patients is principally mediated by outflow obstruction and afterload 
mismatch (19). Nevertheless, when the present analysis was restricted to nonobstructive HCM patients, the 
association between BMI and LV mass persisted, consistent with the concept that cardiac remodeling due 
to excess body weight is largely independent of (although synergistic to) outflow obstruction (12,19).  
Systemic hypertension was another modifier of the HCM phenotype (9,11). As expected, the 
prevalence of elevated blood pressure increased with body weight, and was present in almost 40% of 
obese patients in our HCM cohort. Even though pharmacologically treated according to existing guidelines 
(16), hypertension doubled the likelihood of severe LV hypertrophy in these patients, independent of other 
determinants of LV mass. Furthermore, the combination of obesity and hypertension was associated with 
the highest LV mass values observed for any subset within the cohort. Thus, the present findings support 
the concept that the neurohormonal abnormalities associated with hypertension may impact LV mass in 
HCM patients (14,15,20,31), and thereby represent a relevant therapeutic target (15).  
Conclusions 
The present study provides evidence that obesity is an independent promoter of adverse cardiac 
remodeling associated with increased LV mass in patients with HCM. These observations underscore the 
novel principle that the primary phenotypic expression in this complex, heterogenous heart disease is also 
subject to environmental variables and not solely the product of disease-causing sarcomere mutations. In 
addition, obesity appears to play a role in the development and progression of heart failure symptoms in 
13 
 





1. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2012 Aug 3. [Epub ahead of print] 
2. Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. N Engl J Med 2011;364:1643-56. 
3. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski 
H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA Guideline for the Diagnosis and 
Treatment of Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of 
Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 
2011;124:2761-96.  
4. Olivotto I, Girolami F, Nistri S, Rossi A, Rega L, Garbini F, Grifoni C, Cecchi F, Yacoub MH. The many faces of 
hypertrophic cardiomyopathy: from developmental biology to clinical practice. J Cardiovasc Transl Res. 
2009;2:349-67.  
5. Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy: 
an individualized approach to clinical staging. Circ Heart Fail. 2012;5:535-46. 
6. Ciró E, Nichols PF 3rd, Maron BJ. Heterogeneous morphologic expression of genetically transmitted 
hypertrophic cardiomyopathy. Two-dimensional echocardiographic analysis. Circulation. 1983;67:1227-33. 
7. Wang L, Seidman JG, Seidman CE. Narrative review: harnessing molecular genetics for the diagnosis and 
management of hypertrophic cardiomyopathy. Ann Intern Med. 2010;152:513-20,W181. 
8. Daw EW, Chen SN, Czernuszewicz G, Lombardi R, Lu Y, Ma J, Roberts R, Shete S, Marian AJ. Genome-wide 
mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy. Hum Mol Genet. 
2007;16:2463-71.  
9. Kahn R, Robertson RM, Smith R, Eddy D. The Impact of Prevention on Reducing the Burden of Cardiovascular 
Disease. Circulation 2008;118:576-585. 
10. Parikh NI, Pencina MJ, Wang TJ, Lanier KJ, Fox CS, D'Agostino RB, Vasan RS. Increasing trends in incidence of 
overweight and obesity over 5 decades. Am J Med. 2007;120:242-50. 
11. Heckbert SR, Post W, Pearson GD, Arnett DK, Gomes AS, Jerosch-Herold M, Hundley WG, Lima JA, Bluemke 
DA. Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function 
14 
 
by cardiac magnetic resonance imaging: The multiethnic study of atherosclerosis. J Am Coll Cardiol. 
2006;48:2285-92. 
12. Rider OJ, Francis JM, Ali MK, Byrne J, Clarke K, Neubauer S, Petersen SE. Determinants of left ventricular mass 
in obesity; a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson 2009;11:9.PubMed 
PMID:19393079. 
13. Turkbey EB, McClelland RL, Kronmal RA, Burke GL, Bild DE, Tracy RP, Arai AE, Lima JA, Bluemke DA. The 
impact of obesity on the left ventricle: the Multi-Ethnic Study of Atherosclerosis (MESA). JACC Cardiovasc 
Imaging 2010;3:266-74. 
14. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of 
overweight and obesity in adults—the evidence report. Obes Res. 1998;6(suppl 2):51S–209S. 
15. Abel ED, Litwin SE, Sweeney G. Cardiac Remodeling in Obesity. Physiol Rev 2008;88: 389–419. 
16. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, 
Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA. 
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other 
Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and 
American College of Cardiology Foundation. Circulation 2011;124:2458-73. 
17. Maron MS, Olivotto I, Harrigan C, Appelbaum E, Gibson CM, Lesser JR, Haas TS, Udelson JE, Manning 
WJ, Maron BJ. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a 
primary phenotypic expression of hypertrophic cardiomyopathy. Circulation 2011;124:40-7. 
18. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ. 
Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. 
Circulation. 2006;114:2232-9.  
19. Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, De Santis M, Quarta G, Nistri S, Cecchi F, Salton 
CJ, Udelson JE, Manning WJ, Maron BJ. Assessment and significance of left ventricular mass by 
cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;52:559-66. 
20. Piran S, Liu P, Morales A, Hershberger RE. Where Genome Meets Phenome: Rationale for Integrating Genetic 
and Protein Biomarkers in the Diagnosis and Management of Dilated Cardiomyopathy and Heart Failure. J 
Am Coll Cardiol 2012;60:283–9. 
21. Danias PG, Tritos NA, Stuber M, Kissinger KV, Salton CJ, Manning WJ. Cardiac structure and function in the 
obese: A cardiovascular magnetic resonance imaging study. J Cardiovasc Magn Reson 2003;5:431-8. 
22. Wong CY, O'Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH. Alterations of left ventricular 
myocardial characteristics associated with obesity. Circulation. 2004;110:3081-7. 
23. Maron BJ. Sudden death in hypertrophic cardiomyopathy. J Cardiovasc Transl Res. 2009;2:368-80. 
15 
 
24. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and 
risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342:1778-85. 
25. Olivotto I, Gistri R, Petrone P, Pedemonte E, Vargiu D, Cecchi F. Maximum left ventricular thickness and risk of 
sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003;41:315-21. 
26. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ. Effect of left ventricular 
outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348:295-
303 
27. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the 
risk of heart failure. N Engl J Med 2002;347: 305–313. 
28. Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA. Body mass 
index and mortality in heart failure: a meta-analysis. Am Heart J. 2008;156:13-22. 
29. Grassi G, Seravalle G, Quarti-Trevano F, Scopelliti F, Dell'Oro R, Bolla G, Mancia G. Excessive sympathetic 
activation in heart failure with obesity and metabolic syndrome: characteristics and mechanisms. 
Hypertension. 2007;49:535-41. 
30. Clarke R. Long-term weight loss and prevention of cardiovascular disease. Circulation 2011;124:2801-2. 
31. Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S, DeFreitas G, Entman M, Carabello BA, Roberts 
R, Marian AJ. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the 










Figure 1. Prevalence of LV outflow obstruction in relation to BMI. Bar graph illustrating the proportion of 
patients in each BMI class with LV outflow tract obstruction (≥30 mmHg) at rest or with exercise. Increase 
in BMI is associated with greater likelihood of an obstructive pathophysiology. Symbols: *= p<0.05 vs. 
Normal Weight; §= p<0.05 vs. Pre-Obese.  
Figure 2. Impact of BMI on LV mass. Each panel shows mean (±95% confidence interval for mean) for 
unadjusted LV mass and LV mass index in each of the 3 BMI classes. Overall P value for HCM patients was 
0.005 (obese patients p<0.05 vs. each of the other 2 groups). Abbreviation: Wt = weight. Symbols: *=p<0.05 
vs. Normal weight; †=p<0.05 vs. Pre-Obese.  
Figure 3. Cardiac remodeling in an obese patient with HCM. Images from a 35-year old male patient with a 
BMI of 28 kg/m2. LV mass was 367g (indexed 153 g/m2), with a maximal wall thickness of 29 mm. LV end-
diastolic volume was 235 ml (indexed 97 ml/m2) and LV ejection fraction was 80%. A: CMR SSFP 4-chamber 
showing diffuse thickening with sparing of the apex. B: Corresponding Late gadolinium enhancement (LGE) 
imaging shows lack of fibrosis in LV. Asterisk (*) denotes subcutaneous fat, (+) denotes intrathoracic 
visceral fat. 
Figure 4. Impact of BMI on LV volume and function. Panels show mean (±95% confidence interval for mean) 
LV end-diastolic volume index, LV ejection fraction and stroke volume index  for the 3 BMI classes. Overall P 
values for each variable are provided in Table 1. Abbreviation: Wt = weight. Symbols: *=p<0.05 vs. Normal 
weight; †= p<0.05 vs. Pre-Obese.  
Figure 5. Impact of BMI on survival. Top. Cumulative risk of all-cause mortality in normal weight, pre-obese 
and obese patients during follow-up. Bottom. Prevalence of HCM-related mortality and severe heart failure 
symptoms (NYHA functional classes 3 or 4) among survivors at the end of follow-up period. Abbreviation: 
Wt = weight.  Symbol: * = p=0.03 vs other 2 groups.  
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Table 1.  Clinical and Echocardiographic Features of the 275 HCM Patients in relation to BMI.  
 
  Body Mass Index (Kg/m2)  







No. of Patients n (%) 275 69 (25%) 105 (38%) 101 (37%) 
Male 192 (70%) 32 (46%) 81 (77%) 79 (78%) <0.001
Age at diagnosis  (y) 43±14 41±15 45±13 44±13 0.257
Age at CMR (y) 48±14 46±14 50±14 49±13 0.123
Body surface area (m2) 1.97±0.25 1.73±0.18 1.99±0.2♦ 2.11±0.23§ <0.001
Body Mass Index (Kg/ m2) 29.1±6.1 22.3±2.1 27.4±1.4♦ 35.4±4.8§ <0.001
Height (m) 1.71±0.12 1.68±0.09 1.75±0.12§ 1.68±0.14 <0.001
Weight (Kg) 85±19 63±9 84±11 101±16§ <0.001
NYHA FC at first evaluation    
I 149 (54%) 37 (54%) 64 (61%) 48 (47%) Overall
II 67 (24%) 19 (27%) 22 (21%) 26 (26%) 0.183
III 15 (5%) 3 (4%) 3 (3%) 9 (9%) 
Syncope 57 (20%) 10 (14%) 26 (25%) 21 (21%) 0.263
Atrial Fibrillation 30 (11%) 4 (6%) 12 (11%) 14 (14%) 0.248
Hypertension 75 (27%) 8 (12%) 29 (28%) 38 (38%)♦ 0.001
Type II Diabetes 14 (5%) 4 (4%) 10 (10%) 0.012




Abbreviations: FC= functional class; LV = left ventricular; NYHA = New York Heart Association. 
Symbols: *= only subjects without resting LV outflow obstruction were exercised; # =p<0.05 versus Normal 
(BMI <25).                                                                                                                                                                           
Table 1 (continued) Body Mass Index (Kg/m2) 







Echocardiography   
Left atrial diameter (mm) 44±8 42±7 44±8 46±7# 0.032
LV end-diastolic diameter (mm) 45±6 43±6 45±6 46±6# 0.025
Maximum LV wall thickness 
(mm) 
21±5 22±6 21±5 21±5 0.272
With LV outflow obstruction 107 (39%) 15 (22%) 41 (39%) 51 (50%)# 0.001
        In resting conditions 57 (21%) 10 (14%) 21 (20%) 26 (26%)# 0.201
        Exercise-induced* 50 (18%) 5 (7%) 20 (19%)# 25 (25%)# 0.014
Medical treatment   
Beta-blockers 151 (55%) 28 (40%) 62 (59%) 61 (60%) 0.427
Verapamil 52 (19%) 9 (13%) 22 (21%) 21 (21%) 0.578
Amiodarone 15 (5%) 4 (6%) 6 (6%) 5 (5%) 0.850
Disopyramide 10 (4%) 2 (3%) 4 (4%) 4 (4%) 0.613
Diuretics 29 (10%) 2 (3%) 9 (8%) 18 (18%)# <0.001
ACE-Inhibitors/sartans 40 (14%) 4 (6%) 14 (13%) 22 (21%)# <0.01
Warfarin 14 (5%) 0 5 (5%) 9 (9%) 0.155
   




Abbreviations: BMI=body mass index; LGE=late gadolinium enhancement; LV = left ventricular; NYHA = New 
York Heart Association. 
Symbols: * = p<0.05 versus the other 2 groups, # = p<0.05 versus Normal. 
 
Table 2.  Cardiovascular Magnetic Imaging Findings in 275 HCM Patients with Respect to BMI.  
                        Body Mass Index (Kg/m2)             







No. of Patients n (%) 275 69 (25%) 105 (38%) 101 (37%) 
LV  end-diastolic volume 
(ml) 
151±45 115±29 154±38# 174±45* <0.001
LV  end-diastolic volume 
index (ml/m2) 
77±19 66±14 77±18# 83±20# <0.001
LV  end-systolic volume (ml) 43±22 33±17 44±23# 49±25# <0.001
LV  end-systolic volume 
index (ml/m2) 
22±11 19±9 22±13 23±11# 0.049
LV ejection fraction (%) 72±10  71±11 72±10 72±9  0.864
Stroke volume (ml) 108±33 82±23 109±28# 125±34* <0.001
Stroke volume index (ml/m2) 58±13 52±11* 57±12# 61±15# 0.002
LV mass (g) 205±85 165±84 198±61 240±94* <0.001
LV mass index (g/m2) 104±40 95±46 100±31 114±43* 0.005
Mass volume ratio 1.3±0.5 1.3±0.5 1.3±0.4 1.4±0.5 0.428
Patients with LGE 125 (46%) 19 (28%) 50 (48%)# 55 (55%)# 0.001
LGE mass (g) 22±23 29±25 23±25 18±21 0.432
LGE percent of LV volume 
(%) 













l h b b
BMI Class (Kg/m2)
Norma  Weig t Pre-O ese                     O ese











Normal Wt. Pre-Obese   Obese














Normal Wt. Pre-Obese   Obese










































Normal Wt.   Pre-Obese   Obese
BMI (kg/m2)     <25             25-30          >30
Normal Wt.   Pre-Obese   Obese






































Normal Pre-Obese ObeseNormal Wt.       Pre-Obese Obese
